| abstract |
REFERS TO SPIROINDOLINE-DERIVED COMPOUNDS OF FORMULA (I) WHERE W IS OR U S (O) x, WHERE x IS FROM 0 TO 2; R1 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C10), ARYL, AMONG OTHERS; R2 IS ARYL OR HETEROARYL OPTIONALLY SUBSTITUTED WITH R4, WHERE R4 IS HALOGEN, HYDROXY, C (O) NH2, AMONG OTHERS; R3 IS C (O) N (R5a) (R5b), N (H) C (O) R6, AMONG OTHERS, WHERE R5a, R5b AND R6 ARE EACH H, ALKYL (C1-C6), ALKYL (C2- C6), AMONG OTHERS. PREFERRED COMPOUNDS ARE: N - [(3-CHLOROPYRIDIN-2-IL) METHYL] -1 - [(4-FLUOROPHENYL) SULFONIL] -2-METHYL-1,2,2 ', 3', 5 ', 6'- HEXAHYDROSPIRO [INDOL-3,4'-PYRAN] -5-CARBOXAMIDE; N- (2-CHLOROBENZYL) -1 - [(4-FLUOROPHENYL) SULFONIL] -2-METHYL-1,2,2 ', 3', 5 ', 6'-HEXAHYDROSPIRO [INDOL-3,4'-PYRAN] -5-CARBOXAMIDE; 1 - [(4-FLUOROPHENYL) SULFONIL] -2-METHYL-N - {[3- (TRIFLUOROMETHYL) PYRIDIN-2-IL] METHYL} -1,2,2 ', 3', 5 ', 6'-HEXAHYDROSPIRO [INDOL-3,4'-PYRAN] -5-CARBOXAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE RECEPTOR (GnRH), BEING USEFUL IN THE TREATMENT OF ENDOMETRIOSIS, FIBROIDS IN THE UTERUS, POLYCHISTIC OVARY |